• Migraine Treatment
  The newest novel drug (approved March 9, 2023) for the treatment of migraine is Zavzpret (zavegepant) nasal spray.
• Migraine Prevention
  The newest drug (approved September 28, 2021) for the prevention of migraine (episodic migraine) is Qulipta (atogepant).

New drugs for the treatment of migraine

• The newest drug for the acute treatment of migraine is Zavzpret (zavegepant) nasal spray.
• The newest oral drugs for the acute treatment of migraine are Nurtec ODT (rimegepant) and Ubrelvy (ubrogepant), both orally-administered calcitonin gene-related peptide (CGRP) receptor antagonists (gepants).
• Another new drug for the acute treatment of migraine is Reyvow (lasmiditan), the first serotonin (5-HT)_1F receptor agonist.
• The other new drugs for the acute treatment of migraine are novel formulations of older drugs such as sumatriptan and rizatriptan, belonging to the class of drugs called serotonin (5-HT) receptor agonists (triptans), and dihydroergotamine, an ergotamine derivative.
  • Sumatriptan is a well-established migraine treatment first approved in subcutaneous injection form under the brand name Imitrex in 1992. Sumatriptan is available in a variety of dosage forms, including injection, oral tablets, nasal spray, and nasal powder. Some formulations are also available as generics.
  • Rizatriptan was first approved in an oral tablet formulation under the brand name Maxalt, and an orally disintegrating tablet formulation under the brand name Maxalt-MLT in 1998. Both dosage forms are available as generics. An oral film formulation of rizatriptan was approved under the brand name RizaFilm in 2023.
  • Dihydroergotamine was first approved in injection form under the brand name D.H.E. 45 in 1946 and as a nasal spray under the brand name Migranal in 1997. Some dihydroergotamine formulations are also available as generics.

The following drugs are FDA approved for the acute treatment of migraine with or without aura in adults.